E
Radiopharm Theranostics Limited RADX
$4.26 -$0.02-0.47% NASDAQ
Recommendation
Prev Close
$4.26
Volume
842
Avg Vol (90D)
28,504
Market Cap
$35.38M
Dividend & Yield
--
52-Week Range
$3.50 - $11.00
P/E (TTM)
--
EPS (TTM)
-$0.01
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
7 Best ASX Stocks to Buy Right Now
12/14/2025 - Insider Monkey
Radiopharm Theranostics Announces Change in Substantial Holder Status
12/10/2025 - TipRanks Financial Blog
Radiopharm Theranostics Expands Share Issuance to Bolster Market Position
12/9/2025 - TipRanks Financial Blog
Radiopharm Theranostics Announces New Securities Quotation on ASX
12/9/2025 - TipRanks Financial Blog
Radiopharm Theranostics Announces New Securities Quotation on ASX
12/9/2025 - TipRanks Financial Blog
Radiopharm Theranostics Successfully Passes All Resolutions at General Meeting
12/3/2025 - TipRanks Financial Blog
Radiopharm Theranostics Completes Share Purchase Plan
12/3/2025 - TipRanks Financial Blog
JPMorgan Chase & Co. Ceases Substantial Holding in Radiopharm Theranostics
11/30/2025 - TipRanks Financial Blog
Radiopharm Theranostics (RADX): Analyst Maintains 'Buy' as Price Target Adjusts RADX Stock News
11/26/2025 - GuruFocus
Radiopharm Theranostics Announces Director Change
11/25/2025 - TipRanks Financial Blog
Radiopharm Theranostics Secures Strong Backing at AGM
11/20/2025 - TipRanks Financial Blog
Radiopharm Theranostics Highlights Key Investor Considerations at AGM
11/19/2025 - TipRanks Financial Blog
Radiopharm Theranostics Appoints New Director
11/19/2025 - TipRanks Financial Blog
Radiopharm Theranostics Strengthens Board with Appointment of Bruce Goodwin
11/19/2025 - TipRanks Financial Blog
Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 ...
11/18/2025 - GuruFocus
Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer
11/18/2025 - Globe Newswire
Radiopharm Theranostics Announces 50% Enrollment in Phase 2b Clinical Trial of RAD101 Imaging ...
11/17/2025 - GuruFocus
Radiopharm Theranostics Announces 50% Enrollment in Phase 2b Clinical Trial of RAD101 Imaging in Brain Metastases
11/17/2025 - Globe Newswire
Radiopharm Theranostics starts enrollment of the Third Cohort of Phase 1 Dose Escalation ...
11/12/2025 - GuruFocus
Radiopharm Theranostics starts enrollment of the Third Cohort of Phase 1 Dose Escalation Clinical Trial of 177Lu-RAD204
11/12/2025 - Globe Newswire
Radiopharm Theranostics Advances Phase 1 Trial for Innovative Cancer Treatment
11/12/2025 - TipRanks Financial Blog
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
11/5/2025 - Globe Newswire
Radiopharm Theranostics to Present at Deutsche Bank ADR Virtual Investor Conference
11/3/2025 - TipRanks Financial Blog
Radiopharm Theranostics Director Increases Shareholding
11/3/2025 - TipRanks Financial Blog
CORRECTION -- International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 04, 2025
10/31/2025 - Globe Newswire
Income Statement
Total Revenue (TTM)
$8.00M
EBITDA (TTM)
-$21.12M
EBIT (TTM)
-$22.80M
Net Income (TTM)
-$24.81M
Balance Sheet
Total Assets (Q)
$56.70M
Total Debt (Q)
$0.00
Total Liabilities (Q)
$28.59M
Book Value Per Share (Q)
$0.0124
Cash Flow
Cash from Operations (TTM)
-$23.83M
Cash from Investing (TTM)
$1.20M
Cash from Financing (TTM)
$29.79M
Net Change in Cash (TTM)
$7.16M
Filings
Filing Date
Tuesday, September 16, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Feb 23 and 27 (est)
Price History
Loading...
Beta
--
7-Day Total Return
-7.19%
30-Day Total Return
-19.01%
60-Day Total Return
-34.36%
90-Day Total Return
-12.16%
Year to Date Total Return
-8.19%
1-Year Total Return
-24.33%
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Apr 07, 2025 - $3.50
52-week High
Mar 03, 2025 - $11.00
Valuation
Market Cap
$35.38M - Nano Cap
Enterprise Value
$14.69M
Price/Sales (TTM)
1,252.94
Price/Book (Q)
343.55
Dividends and Shares
Shares Outstanding
2.33K
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.radiopharmtheranostics.com
Phone Number
61 3 9824 5254
Address
62 Lygon Street
Carlton, VIC 3053
Country
Australia
Year Founded
2021
Business Description
Sector
--
Industry
--
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas... more
NASDAQ 12/12/2025 4:00PM Eastern Quotes delayed